Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other EventsItem 8.01 Other Events.
On November 6, 2017, Heat Biologics, Inc. issued a press release announcing that it will deliver pre-clinical data on its Combination Pan-antigen Cytotoxic Therapy (ComPACT™) platform on November 11, 2017, at the 32nd annual Society for Immunotherapy of Cancer (SITC).
The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01Financial Statements and Exhibits.
The following exhibit is filed with this Current Report on Form 8-K:
|
Exhibit Number |
Description |
|
99.1 |
Press Release of Heat Biologics, Inc. dated November 6, 2017 |
HEAT BIOLOGICS, INC. ExhibitEX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release EXHIBIT 99.1 Heat Biologics to Present Data on its ComPACT™ Technology,…To view the full exhibit click here
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
